Axcella Therapeutics’s investigational drug AXA1125 showed promising results in a phase 2a study involving fatigue that persists long after COVID-19 infections.

One of the most common symptoms associated with “long COVID” and reported to the Centers for Disease Control and Prevention is fatigue that interferes with daily life.

In the study, which enrolled 41 participants, those treated with AXA1125 had statistically significant improvements in their levels of mental and physical fatigue.

AXA1125 an endogenous metabolic modulator composed of six amino acids and derivatives. It is also being investigated for patients with non-alcoholic steatohepatitis.